Serum C terminal telopeptide maintains its correlation with bone disease in patients with myeloma even under treatment with bisphosphonates.
Division of Hematology, Department of Oncohematology.
Lara
L
Pochintesta
Silvia
S
Mangiacavalli
Federica
F
Cocito
Alessandra
A
Pompa
Riccardo
R
Albertini
Cristiana
C
Pascutto
Virginia Valeria
VV
Ferretti
Mario
M
Cazzola
Alessandro
A
Corso
D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D001847:Bone Diseases / Q000209:etiology*; D024042:Collagen Type I / Q000097:blood*; D004164:Diphosphonates / Q000627:therapeutic use; D006801:Humans; D009101:Multiple Myeloma / Q000097:blood* / Q000150:complications* / Q000188:drug therapy; D010455:Peptides / Q000097:blood*
D050071:Bone Density Conservation Agents; D024042:Collagen Type I; D004164:Diphosphonates; D010455:Peptides; C052929:collagen type I trimeric cross-linked peptide